<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/E76A7E5C-5DD0-481A-9936-6186CC55E3C7"><gtr:id>E76A7E5C-5DD0-481A-9936-6186CC55E3C7</gtr:id><gtr:name>Avacta Life Sciences Limited</gtr:name><gtr:address><gtr:line1>c/o THE COMPANY SECRETARY
UNIT 20 ASH WAY 
THORP ARCH ESTATE</gtr:line1><gtr:city>WETHERBY</gtr:city><gtr:postCode>LS23 7FA</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/E76A7E5C-5DD0-481A-9936-6186CC55E3C7" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>E76A7E5C-5DD0-481A-9936-6186CC55E3C7</gtr:id><gtr:name>Avacta Life Sciences Limited</gtr:name><gtr:address><gtr:line1>c/o THE COMPANY SECRETARY
UNIT 20 ASH WAY 
THORP ARCH ESTATE</gtr:line1><gtr:city>WETHERBY</gtr:city><gtr:postCode>LS23 7FA</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>63942.0</gtr:offerGrant><gtr:projectCost>106572.0</gtr:projectCost></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/42B8D919-79F1-442C-B7F8-76628749BFAA" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>42B8D919-79F1-442C-B7F8-76628749BFAA</gtr:id><gtr:name>Promexus Limited</gtr:name><gtr:address><gtr:line1>UNIT 651 STREET 5 , THORP ARCH ESTATE</gtr:line1><gtr:city>WETHERBY</gtr:city><gtr:postCode>LS23 7FZ</gtr:postCode><gtr:region>Yorkshire and the Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>35647.0</gtr:offerGrant><gtr:projectCost>59411.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8BE3218D-0D8B-433E-B3E2-7E197AED7F1F"><gtr:id>8BE3218D-0D8B-433E-B3E2-7E197AED7F1F</gtr:id><gtr:firstName>Amrik</gtr:firstName><gtr:surname>Basran</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=710484"><gtr:id>4A235E9F-4294-45C4-BAD6-0F6C1EDA2930</gtr:id><gtr:title>Affimers: a novel biotherapeutic platform for the treatment of cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Concept</gtr:grantCategory><gtr:grantReference>710484</gtr:grantReference><gtr:abstractText>Promexus is a new biotechnology company which will be developing a novel human
therapeutic protein (the Affimer) that will address some of the shortcomings of the current
antibody based drugs. Antibodies have been very successful at treating a wide range of human
disease such as asthma, arthritis and cancer, but they are expensive to produce and because of
their large size can only be given via an injection. Affimers should be cheaper to make and
because they are smaller and stable, can be administered topically (for example to the skin as
a cream or to the lungs using an inhaler). Our first drug will be for the treatment of cancer
where there is a need for cheaper more effective drugs. Affimers have all the properties to
potentially make the next generation of therapeutics to meet the demand of new medicines</gtr:abstractText><gtr:fund><gtr:end>2016-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-06-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>99589</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">710484</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>